Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
10/13/2017 10/16/2017 10/17/2017 10/18/2017 10/19/2017 Date
17.735(c) 17.045(c) 16.69(c) 16.235(c) 16.24 Last
680 055 754 979 478 827 473 874 114 788 Volume
+2.25% -3.89% -2.08% -2.73% +0.03% Change
More quotes
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
Sales 2018 57,4 M
EBIT 2018 -69,0 M
Net income 2018 -70,0 M
Debt 2018 41,7 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 16,8x
EV / Sales2018 18,1x
Capitalization 997 M
More Financials
Company
Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.It offers programs for inflammation, hematology, immuno-oncology, oncology, and respiratory disease.The company was founded on July 4, 2001... 
More about the company
Surperformance© ratings of Ablynx
Trading Rating : Investor Rating :
More Ratings
Latest news on ABLYNX
10/17 ABLYNX : 17/10/2017 ablynx announces launch of proposed global offering
10/17 ABLYNX : Announces launch of proposed global offering
10/16 ABLYNX : 16/10/2017 ablynx establishes subsidiary in the usa and appoints a gene..
10/16 ABLYNX : 16/10/2017 publication in accordance with article 14 of the belgian law..
10/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/13 ABLYNX : 13/10/2017 publication in accordance with article 14 of the belgian law..
10/13 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/06 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/17Ablynx prices $175M U.S. IPO at $20.95  
10/17#IPOs ? Belgian biotech Ablynx sets terms for $175 million global IPO $ABLX $.. 
10/17ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING  
10/17Ablynx : 17/10/2017 ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING  
10/17Ablynx : ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING  
More tweets
Qtime:36
News from SeekingAlpha
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
10/03 YOUR DAILY PHARMA SCOOP : Pfizer A Buy, Our Ablynx Pick Successful, VBLT, DVAX, ..
10/02 Ablynx's caplacizumab successful in late-stage study in rare blood disorder; ..
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,4 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX50.12%1 176
INCYTE CORPORATION14.00%24 360
QUINTILES IMS HOLDINGS INC31.30%21 440
CELLTRION, INC.--.--%20 806
LONZA GROUP64.29%19 850
ALNYLAM PHARMACEUTICALS, INC.228.53%10 889